{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:41:42Z","timestamp":1794220902332,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00415-023-12154-7","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T11:01:21Z","timestamp":1703847681000},"page":"1999-2009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-204X","authenticated-orcid":false,"given":"Federico","family":"Massa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Martinuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"G\u00f3mez de San Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pelagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Kreshpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Abu-Rumeileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Brugnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Girtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Vigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Arnaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Serrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chincarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"12154_CR1","doi-asserted-by":"publisher","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM (2020) Synaptic Health Endpoints Working Group. The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease. Alzheimers Res Ther 12(1):21. https:\/\/doi.org\/10.1186\/s13195-020-00588-4. PMID: 32122400; PMCID: PMC7053087","DOI":"10.1186\/s13195-020-00588-4"},{"key":"12154_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dementia 7:280\u2013292. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003","journal-title":"Alzheimer\u2019s Dementia"},{"key":"12154_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D et al (2019) Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid*. Mol Cell Proteomics 18:546\u2013560. https:\/\/doi.org\/10.1074\/mcp.RA118.001290","journal-title":"Mol Cell Proteomics"},{"key":"12154_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"1979","unstructured":"Selkoe DJ (1979) (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298:789\u2013791","journal-title":"Science"},{"key":"12154_CR5","doi-asserted-by":"publisher","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, Zetterberg H (2020) Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomark Insights 15:1177271920950319. https:\/\/doi.org\/10.1177\/1177271920950319. PMID: 32913390; PMCID: PMC7444114","DOI":"10.1177\/1177271920950319"},{"key":"12154_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ et al (2021) CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. Neurology 97:e2065. https:\/\/doi.org\/10.1212\/WNL.0000000000012853","journal-title":"Neurology"},{"key":"12154_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00702-021-02411-2","volume":"129","author":"G de San","year":"2022","unstructured":"de San G, Jos\u00e9 N, Massa F, Halbgebauer S et al (2022) Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J Neural Transm 129:207\u2013230","journal-title":"J Neural Transm"},{"key":"12154_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.neurobiolaging.2022.07.015","volume":"121","author":"DA Llano","year":"2023","unstructured":"Llano DA, Devanarayan P, Devanarayan V (2023) CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework. Neurobiol Aging 121:15\u201327. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.07.015","journal-title":"Neurobiol Aging"},{"key":"12154_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/jnc.15116","volume":"156","author":"G Sathe","year":"2021","unstructured":"Sathe G, Albert M, Darrow J et al (2021) Quantitative proteomic analysis of the frontal cortex in Alzheimer\u2019s disease. J Neurochem 156:988\u20131002. https:\/\/doi.org\/10.1111\/jnc.15116","journal-title":"J Neurochem"},{"key":"12154_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12179","author":"J Nilsson","year":"2021","unstructured":"Nilsson J, Gobom J, Sj\u00f6din S et al (2021) Cerebrospinal fluid biomarker panel for synaptic dysfunction in alzheimer\u2019s disease. Alzheimer\u2019s Dem Diag Assess Dis Mon. https:\/\/doi.org\/10.1002\/dad2.12179","journal-title":"Alzheimer\u2019s Dem Diag Assess Dis Mon"},{"key":"12154_CR11","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/alz.12353","volume":"17","author":"O Libiger","year":"2021","unstructured":"Libiger O, Shaw LM, Watson MH et al (2021) Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease. Alzheimer\u2019s Dem 17:1976\u20131987. https:\/\/doi.org\/10.1002\/alz.12353","journal-title":"Alzheimer\u2019s Dem"},{"key":"12154_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26725","author":"A Soldan","year":"2023","unstructured":"Soldan A, Oh S, Ryu T et al (2023) NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26725","journal-title":"Ann Neurol"},{"key":"12154_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.23798","author":"M-F Xiao","year":"2017","unstructured":"Xiao M-F, Xu D, Craig MT et al (2017) NPTX2 and cognitive dysfunction in Alzheimer\u2019s Disease. Elife. https:\/\/doi.org\/10.7554\/eLife.23798","journal-title":"Elife"},{"key":"12154_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41597-023-02158-3","volume":"10","author":"CM Watson","year":"2023","unstructured":"Watson CM, Dammer EB, Ping L et al (2023) Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer\u2019s Disease. Sci Data 10:261. https:\/\/doi.org\/10.1038\/s41597-023-02158-3","journal-title":"Sci Data"},{"key":"12154_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103657","author":"A Perna","year":"2021","unstructured":"Perna A, Marathe S, Dreos R et al (2021) Revealing NOTCH-dependencies in synaptic targets associated with Alzheimer\u2019s disease. Mol Cell Neurosci. https:\/\/doi.org\/10.1016\/j.mcn.2021.103657","journal-title":"Mol Cell Neurosci"},{"key":"12154_CR16","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T et al (2015) Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain 138:3373\u20133385. https:\/\/doi.org\/10.1093\/brain\/awv267","journal-title":"Brain"},{"key":"12154_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neurobiolaging.2022.03.019","volume":"117","author":"F Massa","year":"2022","unstructured":"Massa F, Halbgebauer S, Barba L et al (2022) Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer\u2019s disease: preliminary data. Neurobiol Aging 117:212\u2013221","journal-title":"Neurobiol Aging"},{"key":"12154_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dem 7:270\u2013279. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008","journal-title":"Alzheimer\u2019s Dem"},{"key":"12154_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s and Dementia 14:535\u2013562","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"12154_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/joim.12190","volume":"275","author":"RC Petersen","year":"2014","unstructured":"Petersen RC, Caracciolo B, Brayne C et al (2014) Mild cognitive impairment: a concept in evolution. J Intern Med 275:214\u2013228. https:\/\/doi.org\/10.1111\/joim.12190","journal-title":"J Intern Med"},{"key":"12154_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","volume":"6","author":"PS Aisen","year":"2010","unstructured":"Aisen PS, Petersen RC, Donohue MC et al (2010) Clinical core of the Alzheimer\u2019s disease neuroimaging initiative: Progress and plans. Alzheimer\u2019s and Dementia 6:239\u2013246. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.006","journal-title":"Alzheimer\u2019s and Dementia"},{"key":"12154_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jalz.2018.12.009","volume":"15","author":"EC Edmonds","year":"2019","unstructured":"Edmonds EC, McDonald CR, Marshall A et al (2019) Early versus late MCI: Improved MCI staging using a neuropsychological approach. Alzheimer\u2019s Dem 15:699\u2013708. https:\/\/doi.org\/10.1016\/j.jalz.2018.12.009","journal-title":"Alzheimer\u2019s Dem"},{"key":"12154_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00132","author":"A Soldan","year":"2019","unstructured":"Soldan A, Moghekar A, Walker KA et al (2019) Resting-state functional connectivity is associated with cerebrospinal fluid levels of the synaptic protein NPTX2 in non-demented older adults. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2019.00132","journal-title":"Front Aging Neurosci"},{"key":"12154_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","volume":"5","author":"D Galasko","year":"2019","unstructured":"Galasko D, Xiao M, Xu D et al (2019) Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Alzheimer\u2019s Dem Translat Res Clin Intervent 5:871\u2013882. https:\/\/doi.org\/10.1016\/j.trci.2019.11.002","journal-title":"Alzheimer\u2019s Dem Translat Res Clin Intervent"},{"key":"12154_CR25","doi-asserted-by":"publisher","unstructured":"Saura CA, Parra-Damas A, Enriquez-Barreto L (2015) Gene expression parallels synaptic excitability and plasticity changes in Alzheimer\u2019s disease. Front Cell Neurosci 9:318. https:\/\/doi.org\/10.3389\/fncel.2015.00318. PMID: 26379494; PMCID: PMC4548151","DOI":"10.3389\/fncel.2015.00318"},{"key":"12154_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0335-x","author":"FH Duits","year":"2018","unstructured":"Duits FH, Brinkmalm G, Teunissen CE et al (2018) Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-017-0335-x","journal-title":"Alzheimers Res Ther"},{"key":"12154_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: Correlation with cognitive severity. Ann Neurol 27:457\u2013464","journal-title":"Ann Neurol"},{"key":"12154_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0197-4580(90)90059-9","volume":"11","author":"SW Scheff","year":"1990","unstructured":"Scheff SW, DeKosky ST, Price DA (1990) Quantitative assessment of cortical synaptic density in Alzheimer\u2019s disease. Neurobiol Aging 11:29\u201337","journal-title":"Neurobiol Aging"},{"key":"12154_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599771","author":"RA Kov\u00e1cs","year":"2021","unstructured":"Kov\u00e1cs RA, Vad\u00e1szi H, Buly\u00e1ki E et al (2021) Identification of Neuronal Pentraxins as Synaptic Binding Partners of C1q and the Involvement of NP1 in Synaptic Pruning in Adult Mice. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.599771","journal-title":"Front Immunol"},{"key":"12154_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bbi.2016.07.148","volume":"58","author":"A Swanson","year":"2016","unstructured":"Swanson A, Willette AA (2016) Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer\u2019s disease spectrum. Brain Behav Immun 58:201\u2013208. https:\/\/doi.org\/10.1016\/j.bbi.2016.07.148","journal-title":"Brain Behav Immun"},{"key":"12154_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf0141","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wade SD, Graykowski D et al (2023) The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.adf0141","journal-title":"Sci Transl Med"},{"key":"12154_CR32","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-018-4027-y","volume":"45","author":"F Nobili","year":"2018","unstructured":"Nobili F, Schmidt R, Carri\u00f2 I, Frisoni GB (2018) Brain FDG-PET: clinical use in dementing neurodegenerative conditions. Eur J Nucl Med Mol Imaging 45:1467\u20131469","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12154_CR33","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1177\/0271678X211001216","volume":"41","author":"K Provost","year":"2021","unstructured":"Provost K, La Joie R, Strom A et al (2021) Crossed cerebellar diaschisis on 18F-FDG PET: Frequency across neurodegenerative syndromes and association with 11C-PIB and 18F-Flortaucipir. J Cereb Blood Flow Metab 41:2329\u20132343. https:\/\/doi.org\/10.1177\/0271678X211001216","journal-title":"J Cereb Blood Flow Metab"},{"key":"12154_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nn.4492","volume":"20","author":"ER Zimmer","year":"2017","unstructured":"Zimmer ER, Parent MJ, Souza DG et al (2017) [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci 20:393\u2013395. https:\/\/doi.org\/10.1038\/nn.4492","journal-title":"Nat Neurosci"},{"key":"12154_CR35","first-page":"236","volume":"28","author":"T Nakashima","year":"2007","unstructured":"Nakashima T, Nakayama N, Miwa K et al (2007) Focal Brain Glucose Hypometabolism in Patients with Neuropsychologic Deficits after Diffuse Axonal Injury. Am J Neuroradiol 28:236","journal-title":"Am J Neuroradiol"},{"key":"12154_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02988444","volume":"17","author":"K Herholz","year":"2003","unstructured":"Herholz K (2003) PET studies in dementia. Ann Nucl Med 17:79\u201389. https:\/\/doi.org\/10.1007\/BF02988444","journal-title":"Ann Nucl Med"},{"key":"12154_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1006\/nimg.2002.1259","volume":"17","author":"D Soonawala","year":"2002","unstructured":"Soonawala D, Amin T, Ebmeier KP et al (2002) Statistical parametric mapping of 99mTc-HMPAO-SPECT images for the diagnosis of Alzheimer\u2019s disease: Normalizing to cerebellar tracer uptake. Neuroimage 17:1193\u20131202. https:\/\/doi.org\/10.1006\/nimg.2002.1259","journal-title":"Neuroimage"},{"key":"12154_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF02988596","volume":"15","author":"H Matsuda","year":"2001","unstructured":"Matsuda H (2001) Cerebral blood flow and metabolic abnormalities in Alzheimer\u2019s disease. Ann Nucl Med 15:85\u201392. https:\/\/doi.org\/10.1007\/BF02988596","journal-title":"Ann Nucl Med"},{"key":"12154_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-020-00398-0","volume":"15","author":"O Belbin","year":"2020","unstructured":"Belbin O, Xiao MF, Xu D et al (2020) Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer\u2019s disease-related inhibitory circuit dysfunction in adults with down syndrome. Mol Neurodegener 15:1\u201310. https:\/\/doi.org\/10.1186\/s13024-020-00398-0","journal-title":"Mol Neurodegener"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12154-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:10:50Z","timestamp":1711548650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12154-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["12154"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12154-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F Massa has received speaker honorarium from Roche Diagnostic Spa, G\u00f3mez de San Jos\u00e9 N is a part-time employer at Proteintech, S Abu-Rumeileh S received research support from the Medical Faculty of Martin-Luther-University Halle-Wittenberg (Clinician Scientist-Program No. CS22\/06), D Arnaldi received fees from Fidia, Bruno, Italfarmaco, Idorsia for lectures and board participation; A Uccelli, received grants (to his Institution) from FISM, Biogen, Roche, Alexion, Merck Serono; participated on a Data Safety Monitoring Board or Advisory Board (to his Institution) for BD, Biogen, Iqvia, Sanofi, Roche, Alexion, Bristol Myers Squibb; S Morbelli has received speaker Honoraria from G.E. Healthcare; Otto M received fees for advisory board meetings from Roche, Biogen, Grifols, and Axon; M Pardini receives research support from Novartis and Nutricia, received fees from Novartis, Merck. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research involves human participants and was approved by the regional ethical committee (ref:PNRR-POC-2022\u201312376726). Informed consent was obtained from all participants. Anonymized data published per hospital rules for retrospective data collected during the clinical routine. All procedures followed the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and consent to publish"}}]}}